Radiopharmaceuticals Market
Market Insights on Radiopharmaceuticals covering sales outlook, demand forecast & up-to-date key trends
Radiopharmaceuticals Market By Radioisotope Type (Technetium-99, Fluorine-18, Iodine-131, Leutetium-177), Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology), Source (Cyclotrons, Nuclear Reactors) & Region - Forecast 2021 - 2031
Radiopharmaceuticals Market Snapshot
As per Future Market Insights (FMI) analysis, the radiopharmaceuticals market value will total US$ 6107.2 Mn in 2021. Driven by rising prevalence of cancer and cardiovascular diseases, the radiopharmaceuticals market will register steady year-on-year growth CAGR of 4.90% in 2021.
Regionally, North America will contribute over 47% of global market share owing to the increasing prevalence of cancer cases and expansion of healthcare sector in the U.S. and Canada.
As per FMI, Siemens AG (Siemens Healthineers), General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler are identified as prominent players. Leading players contribute nearly 90% of revenue share in the global radiopharmaceuticals market.
Let us know your requirement to get
100% FREE customization
Key Points Covered in Radiopharmaceuticals Market Study
- Market estimates and forecast 2021-2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Radioisotope Innovations and Regulatory Climate
- COVID-19 Impact on Radiopharmaceuticals market and How to Navigate
- Recommendation on Key Winning Strategies
2016-2020 Global Radiopharmaceuticals Market Outlook in Comparison to 2021-2031 Forecast
Improving penetration of radio-therapeutics is expected to be the major driver of the radiopharmaceuticals market. Radiopharmaceuticals are increasingly used in the diagnosis and treatment of several diseases such as cancer, cardiovascular diseases, and neurological disorders.
Owing to characteristics of radioactive decay and ability of targeted therapeutic irradiation, radiopharmaceuticals are extensively used for the treatment of these diseases. However, unprecedented outbreak of COVID-19 severely impacted the growth of the market.
Production of radioisotopes was disrupted across the globe and research activities were halted. Disruption in the demand and supply chain resulted in the drop of global market value.
Nonetheless, FMI predicts the global sales to be up by 4.66% CAGR during the forecast period of 2021 and 2031. Increasing application of nuclear medicine in oncology will create lucrative opportunities by the end of 2031.
Rapid introduction of advanced technologies in nuclear imaging systems such as SPECT and Positron Emission Tomography (PET) will significantly contribute to market growth. Increasing research and development from leading players is aiding the growth of radiopharmaceuticals market.
For instance, GE Healthcare introduced cloud and IT based solutions and apps to connect medical imaging with analytics and insights. Increasing clinical applications of radiopharmaceuticals in oncology, cardiology, endocrinology, and neurology are improving the market growth.
Additionally, increased funding and favorable initiatives from the government will bolster the demand of radiopharmaceuticals across the globe, reaching a valuation of US$ 6107.2 Mn in 2021.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFocus on Developing Centralized Pharmacies Bolstering Growth
The radiopharmaceutical industry has a lack of formalized good manufacturing practice (GMP) guidelines along with stringent policies governing the use of radiopharmaceuticals.
However, to address the quality assurance concerns, nuclear medicine physicians are encouraging establishing centralized radio-pharmacies.
This is due to the growing interest from administrators and legislators in context with regulations for radiopharmaceuticals, Positron Emission Tomography (PET), and for clinical trials.
A centralized radio pharmacy model enforces several advantages to patients as well as governing bodies including minimizing the radiation exposure with ability to dispense patient specific prescription, delivering specified products from all sources and services available.
These initiatives, in turn, are expected to accelerate the market growth over the forecast period.
Country-wise Insights
Why is the U.S. the Most Lucrative Market for Radiopharmaceuticals?
Growth of radiopharmaceuticals market across the U.S. is attributed to the rising prevalence of cancer and cardiovascular diseases in the country. Growing geriatric population and unhealthy living habits resulting in increasing cases of cancer and obesity have improved the sales of nuclear medicines.
Adoption of novel technologies for radioisotope production to treat these diseases is anticipated to bolster the growth of radiopharmaceuticals in the country. According to American Heart Association, around 17.3 million people die each year due to cardiovascular disease.
Radiopharmaceuticals provides an upper hand to the radiologists for the treatment of these diseases. Targeted therapies and advanced technology integrated in cyclotrons for the treatment of cardiovascular disease and cancer will improve the demand for radiopharmaceuticals in the U.S.
Based on these aforementioned factors, the U.S. will lead the North America radiopharmaceuticals market during the forecast period, accounting for over 45% of market share.
Why is the Demand for Radiopharmaceuticals Rising in India?
Expansion of the healthcare sector and adoption of advanced technology are the major factor driving the growth of radiopharmaceuticals market in India. Alongside this, prevalence of cancer cases in the country have bolstered the adoption of targeted therapies and improved the production of radioisotopes.
Increasing preference for non-invasive therapies in India and high efficacy that radiopharmaceuticals provide are the chief reason why radiopharmaceuticals is thriving. Government and private healthcare companies are increasing the funding and research & development activities to develop efficient targeted therapies with less side-effects.
Incorporation of cutting-edge technologies to develop advanced radiotracers for the treatment of cancer and cardiovascular disease are aiding the growth. Several research programs initiated by National Cancer Institute have improved the production and adoption of radioisotopes for the treatment of cancer across India.
For instance, in 2018, the U.S. Food and Drug Administration approved the lutetium Lu 177-dotatate for the treatment of certain cancerous neuroendocrine tumours affecting the digestive tract.
What are the Factors Fueling Demand for Radiopharmaceuticals in Germany?
As per FMI’s analysis, Germany is anticipated to register healthy growth over the forecast period. Germany is anticipated to be the key region leading the growth of Europe’s radiopharmaceuticals market.
Rising adoption of novel technologies including radiotherapy and adoption of radioisotope for cancer treatment have bolstered the demand of radiopharmaceuticals across Germany. Thanks to the presence of leading players across the country, application of nuclear medicine in radiopharmaceuticals is increasing with increasing research & development activities across the country.
Advent of novel technologies such as advanced PET-computed tomography and positron emission tomography-magnetic resonance are facilitating the rising demand of non-invasive therapies for cancer across the country.
Increasing mortality rate in the country due to cancer have compelled the healthcare professionals and governing bodies to improve radioisotope production for usage in molecular imaging and in therapeutic nuclear medicines.
For instance, in 2018, Advancing Nuclear Medicine consortium, led by the Nuclear Research and Consultancy Group (NRG), was awarded a USD7.7 million subsidies to develop FIELD-LAB. This initiative intended to accelerate the development and introduction of new radiopharmaceuticals.
Why is Demand for Radiopharmaceuticals Rising the U.K.?
The U.K. is expected to be a dominant country in Europe, anticipated to account for maximum share in Europe radiopharmaceuticals market.
Rising prevalence of cancer in the U.K. resulted in burgeoning production of radioisotopes to develop advanced molecular imaging and therapies for the cancer treatment. Advantages of radiopharmaceuticals such as high efficacy and non-invasive external monitoring have increased radioisotope production
According to the Cancer Research UK report, approximately 367,167 cases of cancers are diagnosed in the U.K. each year and around 166,000 cancer death recorded every year. Rising situations like this is anticipated to boost the growth of radiopharmaceuticals market across the country.
Expansion of healthcare infrastructure and increasing research on the development of non-invasive targeted therapies to reduce the burden will significantly boost radiopharmaceuticals demand in the U.K.
Growing interest of healthcare professionals, administrators, and legislators in the context with norms for radiopharmaceuticals, positron emission tomography, and clinical trials will certainly aid the market growth.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Insights
Which Radioisotope Will Dominate the Radiopharmaceuticals Market?
Future Market Insights estimates, in terms of radioisotopes technetium-99 will dominate the segment during the assessment period.
As technetium-99 is extensively used in over 85% of the total diagnostic imaging procedure in nuclear medicine, it is anticipated to remain highly preferred radioisotope in the radiopharmaceuticals market.
Growth in demand for technetium-99 is attributed to the long shelf life to perform medical examinations to be done on the patient and protracted half-life.
Why are Cyclotrons Considered Primary Source for Radiopharmaceuticals?
Based on source, the market is segmented into cyclotrons and nuclear reactors. As per Future Market Insights, cyclotrons are expected to dominate the market. Increasing cases of cancer and thyroid across the globe, have increased the application of nuclear medicine in radiopharmaceuticals market.
Widespread availability of the PET scanning machines and PET cyclotron & radiopharmaceutical facility have bolstered the segment growth over the past few years. Rising cases of cancer across the globe will increase the adoption of cyclotron as adoption of radioisotopes increases for the treatment of cancer.
Radiopharmaceuticals are produced either using cyclotrons or in nuclear reactors. The former is expected to hold over 2/3rd of the radiopharmaceuticals market share throughout the assessment period.
Benefit of using cyclotron is the possibility of on-site production of radionuclides of interest which propels the market for radiopharmaceuticals even further. Hence, cyclotrons will dominate the segment over the forecast period, boosting market demand.
Which is the Chief Application of Radiopharmaceuticals?
Rising prevalence of cancer and cardiovascular diseases such as coronary heart disease, heart failure, across the globe are providing a certain boost to the market growth.
Increasing cases of lifestyle disorder, obesity, and tumor due to unhealthy habits among elder population are the major drivers accelerating the demand for radiopharmaceuticals. As per FMI, increasing application in oncology due to rising cases of breast cancer, lung cancer, and prostate cancer will propel the segment growth.
Rising application of nuclear medicine in oncology and cardiology are the chief drivers for the growth of the market. As per American Cancer Society, 1.9 million new cancer cases were reported in 2021, and nearly 608,570 people died due to cancer in the U.S.
With rising new cancer cases healthcare professionals are developing advanced new techniques to develop nuclear medicine for the treatment. Rapid introduction of advanced techniques in radiopharmaceuticals to treat cancer will propel the growth.
Radiopharmaceuticals play an imperative role in the diagnosis and treatment of cancer by providing better understanding of disease staging. FMI estimates, increasing application of nuclear medicine in oncology will garner over 50% of the global market value through 2031.
Competitive Landscape
Severe competition among the key players have led to market consolidation, opines Future Market Insights. Siemens AG, G E Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler are the top 5 players dominating the market.
Nearly 90% of the global market share is held by these top 5 aforementioned players. Offering advanced technology and nuclear medicines for the treatment are among the winning strategies adopted by the top players.
Some of the leading companies such as GE Healthcare and Siemens Healthcare are focusing on introducing new product based technologies, pharmaceutical services, and IT based solutions maintaining their lead in the industry.
- In March 2021, Aktis Oncology, a biotechnology company developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancer cases, announced the completion of a series for solid tumors.
- In November 2020, Canadian radiopharmaceuticals leading company, Fusion Pharmaceuticals announced the collaboration with Anglo-Swedish Pharma leader AstraZeneca to commercialize and develop next-generation alpha emitting radiopharmaceuticals and combination therapies for the treatment of cancer.
Scope of Report
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
USD Million for Value |
|
Key Regions Covered |
North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan. Japan, and Middle East & Africa |
|
Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa |
|
Key Segments Covered |
Radioisotope, Application, Source, End-user, and Regions |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Radiopharmaceuticals Market by Category
By Radioisotope Type:
- Technetium-99
- Fluorine-18
- Iodine-131
- Leutetium-177
- Yttrium-90
- Gallium-68
- Gallium-67
- Rubidium-82
- Iodine-123
- Iodine-125
- Indium-111
- Others
By Application:
- Oncology
- Cardiology
- Gastroenterology
- Neuroendocrinology
- Neurology
- Nephrology
- Others
By Source:
- Cyclotrons
- Nuclear Reactors
By End-User:
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
- Cancer Research Institute
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific excluding Japan
- Japan
- Middle East & Africa (MEA)
Frequently Asked Questions
The radiopharmaceuticals market is expected to surpass a valuation of US$ 6,107.2 Bn in 2021
The radiopharmaceuticals market witnessed steady growth at 5.33% CAGR between 2016 and 2020.
Siemens AG, General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler are the top players leading the radiopharmaceuticals market.
North America accounted for over 47% of global radiopharmaceuticals market, and is expected to hold major share during the forecast period.
Europe radiopharmaceuticals market will exhibit sluggish growth at 4.9% CAGR during the forecast period.
Top countries in terms of radiopharmaceuticals sales are the U.S., the U.K., Germany, India, and China.
Leading players of global radiopharmaceuticals market is expected to contribute nearly 90% of total market share.
Japan, in 2020, accounted for over 11% market share of global radiopharmaceuticals market in 2021.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Global Market Share Analysis
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Macro-Economic Factors
3.1.1. Increasing healthcare expenditure as a percentage of GDP
3.1.2. Rise in Aging population
3.2. Forecast Factors - Relevance & Impact
3.2.1. Increasing Installed base for PET and SPECT Scanners
3.2.2. Increasing Incidence of Cancer
3.2.3. Increasing Diagnosis Rate
3.3. Market Dynamics
3.3.1. Opportunity Analysis
3.3.2. Drivers
3.3.3. Restraints
3.3.4. Trends
4. Market Context
4.1. Reimbursement Scenario
4.2. Key Regulations
4.3. Value Chain Analysis
5. Global Radiopharmaceuticals Market Demand (Size in US$ Mn) Analysis 2016 - 2020 and Forecast, 2021 - 2031
5.1. Historical Market Value (US$ Mn) Analysis, 2016 - 2020
5.2. Current and Future Market Value (US$ Mn) Projections, 2021 - 2031
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
5.3. Market Value Growth Comparison
6. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Radioisotope
6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Mn) Analysis By Radioisotope, 2016–2020
6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Radioisotope, 2021 - 2031
6.3.1. Technetium-99
6.3.2. Fluorine-18
6.3.3. Iodine-131
6.3.4. Leutetium-177
6.3.5. Yttrium-90
6.3.6. Gallium-68
6.3.7. Gallium-67
6.3.8. Rubidium-82
6.3.9. Iodine-123
6.3.10. Iodine-125
6.3.11. Indium-111
6.3.12. Others
6.4. Market Attractiveness Analysis By Radioisotope
7. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Application
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Application, 2016–2020
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2021 - 2031
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Gastroenterology
7.3.4. Neuroendocrinology
7.3.5. Neurology
7.3.6. Nephrology
7.3.7. Others
7.4. Market Attractiveness Analysis By Application
8. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Source
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Source, 2016–2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2021 - 2031
8.3.1. Cyclotrons
8.3.2. Nuclear Reactors
8.4. Market Attractiveness Analysis By Source
9. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016–2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021 - 2031
9.3.1. Hospitals
9.3.2. Diagnostic Imaging Centers
9.3.3. Ambulatory Surgical Centers
9.3.4. Cancer Research Institute
9.4. Market Attractiveness Analysis By End User
10. Global Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2031
10.3.1. North America
10.3.2. Latin America
10.3.3. Western Europe
10.3.4. Eastern Europe
10.3.5. APEJ
10.3.6. Japan
10.3.7. MEA
10.4. Market Attractiveness Analysis By Region
11. North America Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Radioisotope
11.3.3. By Application
11.3.4. By Source
11.3.5. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Radioisotope
11.4.3. By Application
11.4.4. By Source
11.4.5. By End User
12. Latin America Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Rest of Latin America
12.3.2. By Radioisotope
12.3.3. By Application
12.3.4. By Source
12.3.5. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Radioisotope
12.4.3. By Application
12.4.4. By Source
12.4.5. By End User
13. Western Europe Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. UK
13.3.1.3. France
13.3.1.4. Spain
13.3.1.5. Italy
13.3.1.6. Nordic Countries
13.3.1.7. Benelux
13.3.1.8. Rest of WE
13.3.2. By Radioisotope
13.3.3. By Application
13.3.4. By Source
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Radioisotope
13.4.3. By Application
13.4.4. By Source
13.4.5. By End User
14. Eastern Europe Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
14.3.1. By Country
14.3.1.1. Russia
14.3.1.2. Poland
14.3.1.3. Rest of EE
14.3.2. By Radioisotope
14.3.3. By Application
14.3.4. By Source
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Radioisotope
14.4.3. By Application
14.4.4. By Source
14.4.5. By End User
15. APEJ Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
15.3.1. By Country
15.3.1.1. China
15.3.1.2. India
15.3.1.3. Australia & NZ
15.3.1.4. ASEAN
15.3.1.5. Rest of APEJ
15.3.2. By Radioisotope
15.3.3. By Application
15.3.4. By Source
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Radioisotope
15.4.3. By Application
15.4.4. By Source
15.4.5. By End User
16. Japan Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
16.3.1. By Radioisotope
16.3.2. By Application
16.3.3. By Source
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Radioisotope
16.4.2. By Application
16.4.3. By Source
16.4.4. By End User
17. Middle East and Africa Radiopharmaceuticals Market Analysis 2016 - 2020 and Forecast 2021 - 2031
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021 - 2031
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. South Africa
17.3.1.3. Rest of MEA
17.3.2. By Radioisotope
17.3.3. By Application
17.3.4. By Source
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Radioisotope
17.4.3. By Application
17.4.4. By Source
17.4.5. By End User
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep pe (Tentative List)
18.3.1. Siemens AG (Siemens Healthineers)
18.3.1.1. Overview
18.3.1.2. Service Portfolio
18.3.1.3. Profitability by Market Segments (Service/Channel/Region)
18.3.1.4. Sales Footprint
18.3.1.5. Strategy Overview
18.3.1.5.1. Marketing Strategy
18.3.1.5.2. Service Strategy
18.3.1.5.3. Channel Strategy
18.3.2. Positron Corporation
18.3.2.1. Overview
18.3.2.2. Service Portfolio
18.3.2.3. Profitability by Market Segments (Service/Channel/Region)
18.3.2.4. Sales Footprint
18.3.2.5. Strategy Overview
18.3.2.5.1. Marketing Strategy
18.3.2.5.2. Service Strategy
18.3.2.5.3. Channel Strategy
18.3.3. Novartis (Advanced Accelerator Applications)
18.3.3.1. Overview
18.3.3.2. Service Portfolio
18.3.3.3. Profitability by Market Segments (Service/Channel/Region)
18.3.3.4. Sales Footprint
18.3.3.5. Strategy Overview
18.3.3.5.1. Marketing Strategy
18.3.3.5.2. Service Strategy
18.3.3.5.3. Channel Strategy
18.3.4. Curium
18.3.4.1. Overview
18.3.4.2. Service Portfolio
18.3.4.3. Profitability by Market Segments (Service/Channel/Region)
18.3.4.4. Sales Footprint
18.3.4.5. Strategy Overview
18.3.4.5.1. Marketing Strategy
18.3.4.5.2. Service Strategy
18.3.4.5.3. Channel Strategy
18.3.5. GE Healthcare
18.3.5.1. Overview
18.3.5.2. Service Portfolio
18.3.5.3. Profitability by Market Segments (Service/Channel/Region)
18.3.5.4. Sales Footprint
18.3.5.5. Strategy Overview
18.3.5.5.1. Marketing Strategy
18.3.5.5.2. Service Strategy
18.3.5.5.3. Channel Strategy
18.3.6. Lantheus Holdings, Inc.
18.3.6.1. Overview
18.3.6.2. Service Portfolio
18.3.6.3. Profitability by Market Segments (Service/Channel/Region)
18.3.6.4. Sales Footprint
18.3.6.5. Strategy Overview
18.3.6.5.1. Marketing Strategy
18.3.6.5.2. Service Strategy
18.3.6.5.3. Channel Strategy
18.3.7. Sotera Health LLC (Nordion, Inc)
18.3.7.1. Overview
18.3.7.2. Service Portfolio
18.3.7.3. Profitability by Market Segments (Service/Channel/Region)
18.3.7.4. Sales Footprint
18.3.7.5. Strategy Overview
18.3.7.5.1. Marketing Strategy
18.3.7.5.2. Service Strategy
18.3.7.5.3. Channel Strategy
18.3.8. Bayer AG
18.3.8.1. Overview
18.3.8.2. Service Portfolio
18.3.8.3. Profitability by Market Segments (Service/Channel/Region)
18.3.8.4. Sales Footprint
18.3.8.5. Strategy Overview
18.3.8.5.1. Marketing Strategy
18.3.8.5.2. Service Strategy
18.3.8.5.3. Channel Strategy
18.3.9. Eckert & Ziegler
18.3.9.1. Overview
18.3.9.2. Service Portfolio
18.3.9.3. Profitability by Market Segments (Service/Channel/Region)
18.3.9.4. Sales Footprint
18.3.9.5. Strategy Overview
18.3.9.5.1. Marketing Strategy
18.3.9.5.2. Service Strategy
18.3.9.5.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Radiopharmaceuticals Market Value (US$ Mn) Growth Comparison
Table 02: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Radioisotope
Table 03: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Application
Table 04: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Source
Table 05: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By End User
Table 06: Global Radiopharmaceuticals Market Value (US$ Mn) Analysis and Opportunity Assessment 2021 - 2031, By Region
Table 07: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country
Table 08: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 09: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 10: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 11: North America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User
Table 12: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country
Table 13: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 14: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 15: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 16: Latin America Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User
Table 17: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country
Table 18: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 19: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 20: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 21: Western Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User
Table 22: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country
Table 23: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 24: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 25: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 26: Eastern Europe Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User
Table 27: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country
Table 28: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 29: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 30: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 31: APEJ Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User
Table 32: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 33: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 34: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 35: Japan Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User
Table 36: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country
Table 37: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Radioisotope
Table 38: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Application
Table 39: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Source
Table 40: MEA Radiopharmaceuticals Market Value (US$ Mn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By End User 2031
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Radiopharmaceuticals Market Revenue Share by Radioisotope, 2021E & 2031F
Figure 02: Global Radiopharmaceuticals Market Revenue Share by Application, 2021E & 2031F
Figure 03: Global Radiopharmaceuticals Market Revenue Share by Source, 2021E & 2031F
Figure 04: Global Radiopharmaceuticals Market Revenue Share by End User, 2021E & 2031F
Figure 05: Global Radiopharmaceuticals Market Revenue Share by Region, 2021E & 2031F
Figure 06: Radiopharmaceuticals Market Value Analysis and Forecast 2021 – 2031 (US$ Mn)
Figure 07: Radiopharmaceuticals Market Value (US$ Mn), 2016 – 2020
Figure 08: Radiopharmaceuticals Market Absolute $ Opportunity (US$ Mn), 2021 - 2031
Figure 09: Comparison February 2017 and October 2021, Y-o-Y Forecast
Figure 10: Global Radiopharmaceuticals Market Share Analysis (%), By Radioisotope, 2021 & 2031
Figure 11: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Radioisotope, 2021 - 2031
Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 13: Global Radiopharmaceuticals Market Share Analysis (%), By Application, 2021 & 2031
Figure 14: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Application, 2021 - 2031
Figure 15: Global Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 16: Global Radiopharmaceuticals Market Share Analysis (%), By Source, 2021 & 2031
Figure 17: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Source, 2021 - 2031
Figure 18: Global Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 19: Global Radiopharmaceuticals Market Share Analysis (%), By End User, 2021 & 2031
Figure 20: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By End User, 2021 - 2031
Figure 21: Global Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 22: Global Radiopharmaceuticals Market Share Analysis (%), By Region, 2021 & 2031
Figure 23: Global Radiopharmaceuticals Market Y-o-Y Analysis (%), By Region, 2021 - 2031
Figure 24: Global Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Figure 25: North America Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 26: North America Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 27: North America Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 28: North America Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 29: North America Radiopharmaceuticals Market Value Share, By Country (2021 E)
Figure 30: North America Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 31: North America Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 32: North America Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 33: North America Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 34: North America Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 35: North America Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 36: North America Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Figure 37: Latin America Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 38: Latin America Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 39: Latin America Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 40: Latin America Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 41: Latin America Radiopharmaceuticals Market Value Share, By Country (2021 E)
Figure 42: Latin America Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 43: Latin America Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 44: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 45: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 46: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 47: Latin America Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 48: Latin America Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Figure 49: Western Europe Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 50: Western Europe Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 51: Western Europe Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 52: Western Europe Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 53: Western Europe Radiopharmaceuticals Market Value Share, By Country (2021 E)
Figure 54: Western Europe Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 55: Western Europe Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 56: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 57: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 58: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 59: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 60: Western Europe Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Figure 61: Eastern Europe Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 62: Eastern Europe Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 63: Eastern Europe Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 64: Eastern Europe Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 65: Eastern Europe Radiopharmaceuticals Market Value Share, By Country (2021 E)
Figure 66: Eastern Europe Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 67: Eastern Europe Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 68: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 69: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 70: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 71: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 72: Eastern Europe Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Figure 73: APEJ Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 74: APEJ Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 75: APEJ Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 76: APEJ Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 77: APEJ Radiopharmaceuticals Market Value Share, By Country (2021 E)
Figure 78: APEJ Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 79: APEJ Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 80: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 81: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 82: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 83: APEJ Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 84: APEJ Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Figure 85: Japan Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 86: Japan Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 87: Japan Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 88: Japan Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 89: Japan Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 90: Japan Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 91: Japan Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 92: Japan Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 93: Japan Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 94: Japan Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 95: MEA Radiopharmaceuticals Market Value Share, By Radioisotope (2021 E)
Figure 96: MEA Radiopharmaceuticals Market Value Share, By Application (2021 E)
Figure 97: MEA Radiopharmaceuticals Market Value Share, By Source (2021 E)
Figure 98: MEA Radiopharmaceuticals Market Value Share, By End User (2021 E)
Figure 99: MEA Radiopharmaceuticals Market Value Share, By Country (2021 E)
Figure 100: MEA Radiopharmaceuticals Market Value Analysis (US$ Mn), 2016 - 2020
Figure 101: MEA Radiopharmaceuticals Market Value Forecast (US$ Mn), 2021 - 2031
Figure 102: MEA Radiopharmaceuticals Market Attractiveness Analysis by Radioisotope, 2021 - 2031
Figure 103: MEA Radiopharmaceuticals Market Attractiveness Analysis by Application, 2021 - 2031
Figure 104: MEA Radiopharmaceuticals Market Attractiveness Analysis by Source, 2021 - 2031
Figure 105: MEA Radiopharmaceuticals Market Attractiveness Analysis by End User, 2021 - 2031
Figure 106: MEA Radiopharmaceuticals Market Attractiveness Analysis by Region, 2021 - 2031
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
